Drugs / KD6005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06213259 | Jan 2024 → Jan 2025 | rheumatoid arthritis | Shanghai Kanda Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KD6005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06213259 ↗ |
| Route | Subcutaneous | “subcutaneously (SQ)” NCT06213259 ↗ |